Evidence map›Paper›PMID 40573992›Full record

ArticleVaccines2025

Strengthening Vaccine Safety Systems, Research, and Regional Collaboration in Africa: A Call to Action.

Beckie N Tagbo, Chioma S Ejekam, Winfred Oppong-Amoako, Tene Marceline Yameogo, Afework Mitiku, Dorothy O Esangbedo, Nelisiwe Khuzwayo, Gugu Mahlangu, Samia M Badar, Edinam A Agbenu and 2 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Country readiness in responding to COVID-19 Vaccine-Related Events (VREs) in Malawi.Malawi medical journal : the journal of Medical Association of Malawi · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Beckie N TagboAfrica Advisory Committee on Vaccine Safety, WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.ORCID 0000-0002-3590-2691
Chioma S EjekamVaccine Preventable Disease, Universal Health Coverage, Communicable and Non-Communicable Disease Cluster, WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.ORCID 0000-0001-7665-0278
Winfred Oppong-AmoakoAfrica Advisory Committee on Vaccine Safety, WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Tene Marceline YameogoAfrica Advisory Committee on Vaccine Safety, WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.ORCID 0000-0002-2640-1318
Afework MitikuAfrica Advisory Committee on Vaccine Safety, WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Dorothy O EsangbedoAfrica Advisory Committee on Vaccine Safety, WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Nelisiwe KhuzwayoAfrica Advisory Committee on Vaccine Safety, WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Gugu MahlanguAfrica Advisory Committee on Vaccine Safety, WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Samia M BadarVaccine Preventable Disease, Universal Health Coverage, Communicable and Non-Communicable Disease Cluster, WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Edinam A AgbenuVaccine Preventable Disease, Universal Health Coverage, Communicable and Non-Communicable Disease Cluster, WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.ORCID 0009-0001-7056-8991
Rhanda M AdechinaVaccine Preventable Disease, Universal Health Coverage, Communicable and Non-Communicable Disease Cluster, WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.
Kwasi A NyarkoVaccine Preventable Disease, Universal Health Coverage, Communicable and Non-Communicable Disease Cluster, WHO Regional Office for Africa, Brazzaville P.O. Box 06, Congo.

Funding

World Health Organization 001
6 · The paper itself

Abstract

The 8th meeting of the African Advisory Committee on Vaccine Safety (AACVS), constituted in 2021, convened by the Vaccine Research and Innovation Unit within the Vaccine Preventable Diseases Program, WHO Regional Office for Africa, was held virtually from 14 to 16 April 2025. The meeting brought together independent vaccine experts to provide advice to the Regional Director, WHO, on vaccine safety issues critical to the African region. Discussions focused on critical updates regarding ongoing regional outbreaks, safety data, and associated safety concerns, with emphasis on newly introduced vaccines, including the malaria vaccines (RTS, S and R21), the MenFive pentavalent meningitis vaccine, and the Mpox vaccines-MVA-BN and LC16-alongside the ongoing Mpox response. The Committee conducted a deep dive into comprehensive safety considerations for new vaccine introduction, active surveillance strategies, strengthening the responsiveness of pharmacovigilance systems, and advancing vaccine research and development in Africa. Key observations highlighted significant gaps in safety surveillance systems. These included delays in data collection, access, and signal detection; a lack of harmonized real-time monitoring frameworks; the underutilization of digital technologies; and inadequate manufacturer responsibilities and accountability in post-market safety monitoring. The meeting concluded with a call to action emphasizing the need for sustainable pharmacovigilance funding mechanisms, improved regional coordination, real-time data sharing, standardized early safety study protocols, strengthened manufacturer accountability, and investments in risk communication and community engagement to bolster public trust. Strengthening vaccine safety systems and enhancing regional collaboration were recognized as urgent priorities to support the safe and effective deployment of vaccines and protect public health across Africa.

Indexed as

Africamanufacturer accountabilitynew vaccine introductionpharmacovigilanceregional collaborationsafety monitoringvaccine research and developmentvaccine safety

Identifiers

PMID40573992
PMCPMC12197761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.